BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35536548)

  • 21. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
    He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
    Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of the Novel 1
    Zhang XX; Xiao Y; Yan YY; Wang YM; Jiang H; Wu L; Shi JB; Liu XH
    J Med Chem; 2022 Sep; 65(18):12095-12123. PubMed ID: 36068975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
    Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
    Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.
    Schiemann K; Mallinger A; Wienke D; Esdar C; Poeschke O; Busch M; Rohdich F; Eccles SA; Schneider R; Raynaud FI; Czodrowski P; Musil D; Schwarz D; Urbahns K; Blagg J
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1443-51. PubMed ID: 26852363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.
    Ono K; Banno H; Okaniwa M; Hirayama T; Iwamura N; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Apr; 25(8):2336-2350. PubMed ID: 28302507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of CDK8/CycC Ligands with a New Virtual Screening Tool.
    Chen W; Ren X; Chang CA
    ChemMedChem; 2019 Jan; 14(1):107-118. PubMed ID: 30403831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 6-(methylsulfinyl)hexyl isothiocyanate (6-MITC) from Wasabia japonica alleviates inflammatory bowel disease (IBD) by potential inhibition of glycogen synthase kinase 3 beta (GSK-3β).
    Lohning A; Kidachi Y; Kamiie K; Sasaki K; Ryoyama K; Yamaguchi H
    Eur J Med Chem; 2021 Apr; 216():113250. PubMed ID: 33691258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer.
    Velikova TV; Miteva L; Stanilov N; Spassova Z; Stanilova SA
    World J Gastroenterol; 2020 Apr; 26(16):1912-1925. PubMed ID: 32390702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors.
    Lin TE; Yen D; HuangFu WC; Wu YW; Hsu JY; Yen SC; Sung TY; Hsieh JH; Pan SL; Yang CR; Huang WJ; Hsu KC
    Protein Sci; 2024 Jun; 33(6):e5007. PubMed ID: 38723187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Search of Novel CDK8 Inhibitors by Virtual Screening.
    Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
    J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and
    Chen X; Yan Y; Zhang Z; Zhang F; Liu M; Du L; Zhang H; Shen X; Zhao D; Shi JB; Liu X
    J Med Chem; 2021 Aug; 64(16):11857-11885. PubMed ID: 34374541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells.
    Sundberg TB; Choi HG; Song JH; Russell CN; Hussain MM; Graham DB; Khor B; Gagnon J; O'Connell DJ; Narayan K; Dančík V; Perez JR; Reinecker HC; Gray NS; Schreiber SL; Xavier RJ; Shamji AF
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12468-73. PubMed ID: 25114223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.
    Xi M; Chen T; Wu C; Gao X; Wu Y; Luo X; Du K; Yu L; Cai T; Shen R; Sun H
    Eur J Med Chem; 2019 Feb; 164():77-91. PubMed ID: 30594029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased Interleukin-10 Expression by the Inhibition of Ca
    Ohya S; Matsui M; Kajikuri J; Endo K; Kito H
    J Pharmacol Exp Ther; 2021 Apr; 377(1):75-85. PubMed ID: 33504590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of CDK8-associated disorder: two patients with novel CDK8 variants and in vitro and in vivo functional analyses of the variants.
    Uehara T; Abe K; Oginuma M; Ishitani S; Yoshihashi H; Okamoto N; Takenouchi T; Kosaki K; Ishitani T
    Sci Rep; 2020 Oct; 10(1):17575. PubMed ID: 33067521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel 3-hydroxyandrosta-5,7-Diene-17-Carboxylic acid derivatives as anti-inflammatory bowel diseases (IBD) agents.
    Chen J; Li L; Liu J; Yuan S; Liao W; Slominski AT; Li W; Żmijewski MA; Chen J
    Eur J Med Chem; 2021 Aug; 220():113468. PubMed ID: 33933753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of pyrimidine-5-carboxamide derivatives as novel salt-inducible kinases (SIKs) inhibitors for inflammatory bowel disease (IBD) treatment.
    Cai X; Wang L; Yi Y; Deng D; Shi M; Tang M; Li N; Wei H; Zhang R; Su K; Ye H; Chen L
    Eur J Med Chem; 2023 Aug; 256():115469. PubMed ID: 37178481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. All-Atomic Molecular Dynamic Studies of Human and
    Xu W; Xie XJ; Faust AK; Liu M; Li X; Chen F; Naquin AA; Walton AC; Kishbaugh PW; Ji JY
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
    Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.